Clarity Pharmaceuticals Posts Wider Half-Year Loss but Lifts Net Tangible Assets

Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an update.

Clarity Pharmaceuticals reported no revenue from ordinary activities for the half-year to 31 December 2025, while its net loss attributable to owners widened sharply to about A$55.6 million. The company did not pay or declare any dividends for the period, but its net tangible assets per share rose to 62.6 cents from 39.7 cents, suggesting a stronger asset backing despite ongoing losses.

The group also wound up its European subsidiary, Clarity Pharmaceuticals Europe SA, on 31 December 2025, resulting in a loss of control over that entity as part of its restructuring moves. The half-year consolidated financial statements received an unmodified review opinion from auditor Grant Thornton, providing assurance over the reported figures amid the company’s continuing investment and loss-making phase.

The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.40 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd is an Australia-based biopharmaceutical company focused on developing radiopharmaceutical products. The company operates in the healthcare and life sciences sector, targeting diagnostic and therapeutic applications using advanced radioactive imaging and treatment technologies for cancer and other serious diseases.

Average Trading Volume: 2,178,156

Technical Sentiment Signal: Buy

Current Market Cap: A$1.34B

See more data about CU6 stock on TipRanks’ Stock Analysis page.